Robert W. Baird reiterated their hold rating on shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) in a research note issued to investors on Tuesday. Robert W. Baird currently has a $7.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $9.00.

FOLD has been the topic of a number of other reports. Zacks Investment Research downgraded Amicus Therapeutics from a hold rating to a sell rating in a research report on Tuesday, October 18th. Chardan Capital set a $15.00 price objective on Amicus Therapeutics and gave the company a buy rating in a research report on Thursday, August 11th. Cowen and Company restated an outperform rating and set a $15.00 price objective on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. Finally, Leerink Swann restated a buy rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $11.31.

Amicus Therapeutics (NASDAQ:FOLD) opened at 6.51 on Tuesday. The stock has a 50 day moving average price of $7.82 and a 200-day moving average price of $6.97. Amicus Therapeutics has a 1-year low of $4.98 and a 1-year high of $11.02. The stock’s market cap is $926.54 million.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $1.71 million. On average, equities analysts expect that Amicus Therapeutics will post ($1.38) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2016/11/30/amicus-therapeutics-inc-fold-given-hold-rating-at-robert-w-baird.html.

In other Amicus Therapeutics news, SVP Daphne Quimi sold 8,546 shares of the company’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $8.00, for a total transaction of $68,368.00. Following the completion of the sale, the senior vice president now owns 24,189 shares in the company, valued at $193,512. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Hung Do sold 25,000 shares of the company’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $7.00, for a total value of $175,000.00. Following the sale, the insider now owns 583,453 shares of the company’s stock, valued at approximately $4,084,171. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

A number of hedge funds have recently bought and sold shares of FOLD. UBS Group AG raised its stake in Amicus Therapeutics by 37.7% in the first quarter. UBS Group AG now owns 88,282 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 24,155 shares in the last quarter. Squarepoint Ops LLC raised its stake in Amicus Therapeutics by 101.9% in the first quarter. Squarepoint Ops LLC now owns 83,600 shares of the biopharmaceutical company’s stock worth $706,000 after buying an additional 42,200 shares in the last quarter. GW&K Investment Management LLC raised its stake in Amicus Therapeutics by 12.3% in the second quarter. GW&K Investment Management LLC now owns 468,708 shares of the biopharmaceutical company’s stock worth $2,559,000 after buying an additional 51,273 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock worth $3,876,000 after buying an additional 90,000 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock worth $3,545,000 after buying an additional 107,215 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.